Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine
Maik Tretbar(Leipzig University), Finn K. Hansen(University of Bonn)
Cited by 1
Related Papers
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
|Pharmaceuticals|2023|28
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders
|Journal of Medicinal Chemistry|2025|13
Development of the first geldanamycin-based HSP90 degraders
|Frontiers in Chemistry|2023|11
Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with anti-leukemic activity
|ChemRxiv|2022|5
DCAF16‐Based Covalent Molecular Glues for Targeted Protein Degradation of Histone Deacetylases
|Archiv der Pharmazie|2025|2